Drug-price transparency tracker showing US vs global prices and deal concessions

Drug-price transparency tracker showing US vs global prices and deal concessions targets a $3.6B = 18,000 potential institutional buyers × $200K ACV (payers, PBMs, large employers, gov agencies, research institutions) total addressable market with medium saturation and a year-over-year growth rate of 11% CAGR (healthcare analytics and transparency market; source: Grand View Research and industry reports).

Key trends driving demand: Regulatory pressure — governments and regulators are increasingly requiring price disclosures and reporting, creating demand for normalized, auditable price datasets.; Cross-border arbitrage concern — media and policymakers are focused on large US vs international price gaps, making comparative tools newsworthy and policy-relevant.; Data availability and AI extraction — more procurement and regulatory documents are digitized and LLM-based extraction makes structured concessions data feasible at scale.; Employer cost-containment — large self-insured employers are actively shopping for transparent drug pricing tools to control benefit spend, creating a buyer cohort willing to pay..